Tyrosine kinase inhibitors (TKI): others

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Tyrosine kinase inhibitors (TKI): others. Myelosuppression, Hepatotoxicity, Pancreatitis, Arterial thrombosis. Fully referenced neurology checklist.

Ponatinib complications

  • Myelosuppression
  • Hepatotoxicity
  • Pancreatitis
  • Arterial thrombosis
  • Pityriasis rubra pilaris-like lesions
  • Ichthyosiform eruptions
  • Facial erythema
  • Arterial thrombosis
  • Hypertension

Regorafenib complications

Locked: subscribe to see this section.

Bosutinib complications

Locked: subscribe to see this section.

Sorafenib complications

Locked: subscribe to see this section.

Other TKIs causing posterior reversible encephalopathy syndrome (PRES)

Locked: subscribe to see this section.

Other TKIs causing myasthenia gravis

Locked: subscribe to see this section.

TKIs causing QTc interval prolongation

Locked: subscribe to see this section.

Other TKI complications

Locked: subscribe to see this section.

References

  1. Shamroe CL, Comeau JM. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother 2013; 47:1540-1546.
  2. Eber AE, Rosen A, Oberlin KE, Giubellino A, Romanelli P. Ichthyosiform pityriasis rubra pilaris-like eruption secondary to ponatinib therapy: case report and literature review. Drug Saf Case Rep 2017; 4:19.
  3. Krygier J, Leemans G, Forsyth R, de Becker A, Gutermuth J, Grosber M. A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor. Ann Dermatol Venereol 2018; 145:665-670.
  4. Munera-Campos M, Carrascosa JM, Quer A, Ferrándiz C. Ichthyosiform eruption and facial erythema secondary to ponatinib therapy. J Dtsch Dermatol Ges 2020; 18:743-747. 
  5. Haguet H, Bouvy C, Delvigne AS, et al. The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study. Front Pharmacol 2020; 11:1007. 
  6. And 28 more. Subscribe to see the full list

Related checklists

Loading...